Developer docs
API playgroundTry for free, no card

Search company profiles

Moonlight Bio

Full company profile

uuid0005vy4

Namestring
Moonlight Bio
Legal namestring
Moonlight Bio, Inc.
Websiteurl
moonlightbio.us
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Moonlight Bio is a Seattle-based, privately held biotechnology company founded in 2023 that develops engineered T cell therapies for solid tumors. The company's core proposition is the systematic identification of evolutionary T cell adaptations — using a proprietary mutation library derived from human studies — to engineer cell therapies with improved function against solid tumor biology. A 2024 Nature publication co-authored by scientific founders Kole Roybal and Jaehyuk Choi of UCSF provides peer-reviewed validation of the underlying biology.

The technology platform centers on a mutation library that enables screening of T cell adaptations, with a lead cell therapy candidate advancing toward clinical study. Supporting infrastructure is built through an ecosystem of external partners: MaxCyte (electroporation/cell engineering instruments), Biocytogen (immunodeficient mouse models for in vivo efficacy), Leveragen (genetic models), Kincell Bio (manufacturing and clinical translation support), ZenQMS (quality management systems), and ScaleReady (G-Rex manufacturing platform, accessed via grant). Moonlight Bio is led by founding scientific talent from UCSF with broader team experience drawn from prior cell therapy companies including Juno and bluebird bio.

The company operates as a pre-clinical/clinical-stage biotech with no commercial product and no recurring revenue. Its capital sources include Venrock, PICI (Parker Institute for Cancer Immunotherapy), Yosemite, and individual investor Peter Fenton. The business model is typical of an early-stage cell therapy developer: invest capital to advance therapeutic candidates through preclinical and clinical milestones, with the long-term monetization path oriented toward out-licensing, partnership, or commercialization. The lead candidate is the principal near-term value driver.

Short descriptiontext

Moonlight Bio is a Seattle-based pre-clinical biotech that uses a proprietary library of evolutionary T cell mutations to engineer cell therapies for solid tumors, advancing its lead candidate toward clinical study.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
adoptive cell therapy, T cell engineering, solid tumor treatment, cancer immunotherapy, cell therapy platform
Industry2 codes
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cancer Immunotherapy / Cell Therapy
Social media profiles1 record
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Moonlight Bio develops a proprietary suite of potency enhancement technologies that harness evolutionary T cell adaptations — naturally occurring genetic mutations identified through 'experiments of nature' in human T cells — to engineer adoptive T cell therapies targeting solid tumors. The company sequences dominant T cell clones from humans, generates libraries of diverse mutation types, screens for favorable profiles, and develops cell therapies with evolution-backed enhancement to address challenges of poor T cell proliferation, persistence, exhaustion, limited tumor infiltration, and immunosuppressive tumor microenvironment.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • T cell mutations dramatically increase potency of T cells targeting a variety of tumors in model systems
Product overview1 text field

Moonlight Bio is a Seattle-based biotechnology company developing a pipeline of enhanced T cell therapies for solid tumors. Its core offering consists of a proprietary suite of potency enhancement technologies that leverage naturally occurring T cell mutations identified through the study of evolutionary adaptations in human T cells. These genetic events are compiled into libraries, screened for favorable profiles, and delivered to therapeutic T cells to overcome barriers such as poor proliferation, T cell exhaustion, limited tumor infiltration, and the immunosuppressive tumor microenvironment. The company's lead cell therapy candidate is advancing toward clinical study, with support from partners including Kincell Bio, Biocytogen, Leveragen, and MaxCyte.

Product and service1 record
1Proprietary Potency Enhancement Technologies (T Cell Enhancement Platform)
Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-23
Description

Biocytogen Pharmaceuticals (Beijing-based, listed on SSE and HKEX) partnered with Moonlight Bio in March 2026 to develop cutting-edge cell therapies for difficult-to-treat cancers. Under the agreement, Biocytogen provides its off-the-shelf fully human antibody library against therapeutic targets, while Moonlight Bio leads preclinical development and leverages its cell therapy technologies to address solid tumor limitations. The partnership combines Biocytogen's antibody discovery platforms with Moonlight Bio's cell therapy technologies.

Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-02-23
Description

ZenQMS announced a collaboration with Moonlight Bio to deliver a right-sized eQMS (electronic quality management system) solution to support Moonlight Bio's operational and quality compliance needs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-07
Description

Kincell Bio announced a collaboration to advance Moonlight Bio's lead cell therapy candidate to clinical study. This collaboration supports the progression of Moonlight Bio's most advanced therapy program toward clinical investigation.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-10-06
Description

MaxCyte, a cell-engineering company, entered into a strategic platform license (SPL) agreement with Moonlight Bio to advance T cell therapies for solid tumors. MaxCyte provides its SPL platform to support Moonlight Bio's cell engineering needs. This was announced as a new SPL client, bringing MaxCyte's total SPL agreements to 32.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-29
Description

Leveragen, a Boston-based biotechnology company, entered into a strategic collaboration with Moonlight Bio to advance T cell therapies using Leveragen's proprietary fully human single-domain antibody technology. Leveragen holds Japan Patent No. JP7799706 for its Singularity Platform for single-domain antibody discovery. The collaboration leverages Leveragen's antibody technology in combination with Moonlight Bio's cell therapy platforms.

Strategic tierMinorTypeOthersAnnounced on2024-12-18
Description

ScaleReady awarded a G-Rex Grant to Moonlight Bio. G-Rex is a proprietary bioreactor platform for cell therapy manufacturing. The grant provides Moonlight Bio with access to ScaleReady's G-Rex technology for cell therapy production.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage cell therapy company developing engineered T cell therapies targeting cancer and autoimmune diseases. Comparable as a T cell therapy platform player working on enhanced T cell approaches.

TypeDirect peer
Description

Clinical-stage cell therapy company developing engineered cell therapies for cancer and other diseases. Notably, Moonlight Bio's VP Legal Tony Parenti previously worked at Sana Biotechnology, indicating relevant talent overlap.

TypeDirect peer
Description

Clinical-stage T cell therapy company developing enhanced T cell therapies to address solid tumor challenges including exhaustion and persistence. Direct comparable on solid tumor T cell therapy platforms with proprietary enhancement strategies.

TypeDirect peer
Description

Clinical-stage cell therapy company developing engineered TCR-T cell therapies for solid tumors. Highly relevant peer given shared focus on enhanced T cell potency against solid tumor indications, though with a TCR-engineering rather than mutation-enhancement approach.

TypeBroad incumbent
Description

Pioneering CAR-T therapy company (now part of Bristol Myers Squibb) with deep expertise in engineered T cell therapies for hematological and solid tumors. Moonlight Bio's CMO previously worked at Juno, and the company serves as a benchmark for T cell therapy development and commercialization trajectories.

TypeDirect peer
Description

Clinical-stage cell therapy company developing engineered T cell therapies, including approaches with enhanced potency. Notably, Moonlight Bio's CMO Nick Trede previously held roles at Century Therapeutics, indicating direct talent and technology overlap.

TypeDirect peer
Description

Clinical-stage cell therapy company developing allogeneic CAR-T therapies with next-generation approaches to overcome solid tumor limitations. Comparable to Moonlight Bio on the cell therapy modality and solid tumor focus.

8Bluebird Bio
TypeBroad incumbent
Description

Commercial-stage gene and cell therapy company with experience in autologous engineered cell therapies. Relevant as a broader comparable in the engineered cell therapy space, particularly given the talent pedigree of Moonlight Bio's leadership team.

TypeDirect peer
Description

Clinical-stage cell therapy company focused on engineered T cell therapies for cancer, including next-generation approaches to overcome solid tumor barriers. Direct comparable on adoptive T cell therapy development with Moonlight Bio's approach.

TypeBroad incumbent
Description

Commercial-stage cell therapy leader focused on tumor-infiltrating lymphocyte (TIL) therapies for solid tumors. Provides a reference point for cell therapy commercial economics in solid tumor indications Moonlight is targeting.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Moonlight Bio

Cancer Immunotherapy / Cell Therapymoonlightbio.us

Moonlight Bio is a Seattle-based pre-clinical biotech that uses a proprietary library of evolutionary T cell mutations to engineer cell therapies for solid tumors, advancing its lead candidate toward clinical study.

What Moonlight Bio does

Moonlight Bio is a Seattle-based, privately held biotechnology company founded in 2023 that develops engineered T cell therapies for solid tumors. The company's core proposition is the systematic identification of evolutionary T cell adaptations — using a proprietary mutation library derived from human studies — to engineer cell therapies with improved function against solid tumor biology. A 2024 Nature publication co-authored by scientific founders Kole Roybal and Jaehyuk Choi of UCSF provides peer-reviewed validation of the underlying biology.

The technology platform centers on a mutation library that enables screening of T cell adaptations, with a lead cell therapy candidate advancing toward clinical study. Supporting infrastructure is built through an ecosystem of external partners: MaxCyte (electroporation/cell engineering instruments), Biocytogen (immunodeficient mouse models for in vivo efficacy), Leveragen (genetic models), Kincell Bio (manufacturing and clinical translation support), ZenQMS (quality management systems), and ScaleReady (G-Rex manufacturing platform, accessed via grant). Moonlight Bio is led by founding scientific talent from UCSF with broader team experience drawn from prior cell therapy companies including Juno and bluebird bio.

The company operates as a pre-clinical/clinical-stage biotech with no commercial product and no recurring revenue. Its capital sources include Venrock, PICI (Parker Institute for Cancer Immunotherapy), Yosemite, and individual investor Peter Fenton. The business model is typical of an early-stage cell therapy developer: invest capital to advance therapeutic candidates through preclinical and clinical milestones, with the long-term monetization path oriented toward out-licensing, partnership, or commercialization. The lead candidate is the principal near-term value driver.

Moonlight Bio firmographics

Firmographics
Name
Moonlight Bio
Legal name
Moonlight Bio, Inc.
Website
https://moonlightbio.us
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Short description
Moonlight Bio is a Seattle-based pre-clinical biotech that uses a proprietary library of evolutionary T cell mutations to engineer cell therapies for solid tumors, advancing its lead candidate toward clinical study.
Ownership category
akta.pro rank

Moonlight Bio industry classification

Industry
Product category
Cancer Immunotherapy / Cell Therapy
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Adoptive cell therapy
  • T cell engineering
  • Solid tumor treatment
  • Cancer immunotherapy
  • Cell therapy platform

Where Moonlight Bio is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Markets served

Moonlight Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Marketing channels3 records

Moonlight Bio product offering

Product offering

Core offering

Moonlight Bio develops a proprietary suite of potency enhancement technologies that harness evolutionary T cell adaptations — naturally occurring genetic mutations identified through 'experiments of nature' in human T cells — to engineer adoptive T cell therapies targeting solid tumors. The company sequences dominant T cell clones from humans, generates libraries of diverse mutation types, screens for favorable profiles, and develops cell therapies with evolution-backed enhancement to address challenges of poor T cell proliferation, persistence, exhaustion, limited tumor infiltration, and immunosuppressive tumor microenvironment.

Product overview

Moonlight Bio is a Seattle-based biotechnology company developing a pipeline of enhanced T cell therapies for solid tumors. Its core offering consists of a proprietary suite of potency enhancement technologies that leverage naturally occurring T cell mutations identified through the study of evolutionary adaptations in human T cells. These genetic events are compiled into libraries, screened for favorable profiles, and delivered to therapeutic T cells to overcome barriers such as poor proliferation, T cell exhaustion, limited tumor infiltration, and the immunosuppressive tumor microenvironment. The company's lead cell therapy candidate is advancing toward clinical study, with support from partners including Kincell Bio, Biocytogen, Leveragen, and MaxCyte.

Differentiator

Problem solved

Functional benefit

Products and services

  • Proprietary Potency Enhancement Technologies (T Cell Enhancement Platform)

Quantifiable outcome

  • T cell mutations dramatically increase potency of T cells targeting a variety of tumors in model systems

Companies that use Moonlight Bio

Customer profile

Segments1 record

Ideal customer profiles3 records

Moonlight Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Moonlight Bio partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Biocytogen PharmaceuticalscoreStrategic or Co-development Partner · 23 March 2026Biocytogen Pharmaceuticals (Beijing-based, listed on SSE and HKEX) partnered with Moonlight Bio in March 2026 to develop cutting-edge cell therapies for difficult-to-treat cancers. Under the agreement, Biocytogen provides its off-the-shelf fully human antibody library against therapeutic targets, while Moonlight Bio leads preclinical development and leverages its cell therapy technologies to address solid tumor limitations. The partnership combines Biocytogen's antibody discovery platforms with Moonlight Bio's cell therapy technologies.
  • ZenQMSminorImplementation/ SI/ Consulting Partner · 23 February 2026ZenQMS announced a collaboration with Moonlight Bio to deliver a right-sized eQMS (electronic quality management system) solution to support Moonlight Bio's operational and quality compliance needs.
  • Kincell BiocoreStrategic or Co-development Partner · 7 October 2025Kincell Bio announced a collaboration to advance Moonlight Bio's lead cell therapy candidate to clinical study. This collaboration supports the progression of Moonlight Bio's most advanced therapy program toward clinical investigation.
  • MaxCytecoreTechnology or Integration · 6 October 2025MaxCyte, a cell-engineering company, entered into a strategic platform license (SPL) agreement with Moonlight Bio to advance T cell therapies for solid tumors. MaxCyte provides its SPL platform to support Moonlight Bio's cell engineering needs. This was announced as a new SPL client, bringing MaxCyte's total SPL agreements to 32.
  • LeveragencoreStrategic or Co-development Partner · 29 January 2025Leveragen, a Boston-based biotechnology company, entered into a strategic collaboration with Moonlight Bio to advance T cell therapies using Leveragen's proprietary fully human single-domain antibody technology. Leveragen holds Japan Patent No. JP7799706 for its Singularity Platform for single-domain antibody discovery. The collaboration leverages Leveragen's antibody technology in combination with Moonlight Bio's cell therapy platforms.
  • ScaleReadyminorOthers · 18 December 2024ScaleReady awarded a G-Rex Grant to Moonlight Bio. G-Rex is a proprietary bioreactor platform for cell therapy manufacturing. The grant provides Moonlight Bio with access to ScaleReady's G-Rex technology for cell therapy production.

Recent moves5 records

Expansion highlights5 records

Moonlight Bio competitors and assessment

Company assessment

Direct peers

  • Cabaletta Bio: Clinical-stage cell therapy company developing engineered T cell therapies targeting cancer and autoimmune diseases. Comparable as a T cell therapy platform player working on enhanced T cell approaches.
  • Sana Biotechnology: Clinical-stage cell therapy company developing engineered cell therapies for cancer and other diseases. Notably, Moonlight Bio's VP Legal Tony Parenti previously worked at Sana Biotechnology, indicating relevant talent overlap.
  • Lyell Immunopharma: Clinical-stage T cell therapy company developing enhanced T cell therapies to address solid tumor challenges including exhaustion and persistence. Direct comparable on solid tumor T cell therapy platforms with proprietary enhancement strategies.
  • Adaptimmune Therapeutics: Clinical-stage cell therapy company developing engineered TCR-T cell therapies for solid tumors. Highly relevant peer given shared focus on enhanced T cell potency against solid tumor indications, though with a TCR-engineering rather than mutation-enhancement approach.
  • Century Therapeutics: Clinical-stage cell therapy company developing engineered T cell therapies, including approaches with enhanced potency. Notably, Moonlight Bio's CMO Nick Trede previously held roles at Century Therapeutics, indicating direct talent and technology overlap.
  • Allogene Therapeutics: Clinical-stage cell therapy company developing allogeneic CAR-T therapies with next-generation approaches to overcome solid tumor limitations. Comparable to Moonlight Bio on the cell therapy modality and solid tumor focus.
  • 2seventy bio: Clinical-stage cell therapy company focused on engineered T cell therapies for cancer, including next-generation approaches to overcome solid tumor barriers. Direct comparable on adoptive T cell therapy development with Moonlight Bio's approach.

Broad incumbents

  • Juno Therapeutics (acquired by Bristol Myers Squibb): Pioneering CAR-T therapy company (now part of Bristol Myers Squibb) with deep expertise in engineered T cell therapies for hematological and solid tumors. Moonlight Bio's CMO previously worked at Juno, and the company serves as a benchmark for T cell therapy development and commercialization trajectories.
  • Bluebird Bio: Commercial-stage gene and cell therapy company with experience in autologous engineered cell therapies. Relevant as a broader comparable in the engineered cell therapy space, particularly given the talent pedigree of Moonlight Bio's leadership team.
  • Iovance Biotherapeutics: Commercial-stage cell therapy leader focused on tumor-infiltrating lymphocyte (TIL) therapies for solid tumors. Provides a reference point for cell therapy commercial economics in solid tumor indications Moonlight is targeting.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Moonlight Bio social profiles

Digital presence

Moonlight Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Moonlight Bio leadership team

Management profile

Number of profiles

Profiles7 records

Moonlight Bio funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Moonlight Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Moonlight Bio

What does Moonlight Bio do?

Moonlight Bio develops a proprietary suite of potency enhancement technologies that harness evolutionary T cell adaptations — naturally occurring genetic mutations identified through 'experiments of nature' in human T cells — to engineer adoptive T cell therapies targeting solid tumors. The company sequences dominant T cell clones from humans, generates libraries of diverse mutation types, screens for favorable profiles, and develops cell therapies with evolution-backed enhancement to address challenges of poor T cell proliferation, persistence, exhaustion, limited tumor infiltration, and immunosuppressive tumor microenvironment.

Is Moonlight Bio a public or private company?

Moonlight Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Moonlight Bio founded?

Moonlight Bio was founded in 2023. It employs 11 to 50 people.

Where is Moonlight Bio based?

Moonlight Bio is headquartered in Seattle, United States, in the North America region.

Who are Moonlight Bio's main competitors?

Direct peers on record are Cabaletta Bio, Sana Biotechnology, Lyell Immunopharma, Adaptimmune Therapeutics, Century Therapeutics, Allogene Therapeutics and 2seventy bio. Broad incumbents are Juno Therapeutics (acquired by Bristol Myers Squibb), Bluebird Bio and Iovance Biotherapeutics.

Does Moonlight Bio have an API?

No public API is recorded for Moonlight Bio.

What industry is Moonlight Bio in?

Moonlight Bio's product category is Cancer Immunotherapy / Cell Therapy. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Spherical InsightsAntibody Discovery Market Insights Forecasts to 2035Spherical Insights & Consulting published a market research report projecting the global antibody discovery market to grow from USD 1.781 billion in 2024 to USD 6.434 billion by 2035, representing a compound annual growth rate of 12.39%. The report attributes market expansion to rising chronic disease prevalence, increased demand for targeted biologics, and technological advancements in AI-enabled discovery platforms. Two notable partnerships were reported: Biocytogen Pharmaceuticals partnered with Moonlight Bio in March 2026 to develop cell therapies for hard-to-treat cancers, and Harbour BioMed strengthened its collaboration with Spruce Biosciences in January 2026 for antibody therapeutics development.Business Wire IndiaBiocytogen Announces Strategic Collaboration with Moonlight Bio to Advance Cell Therapies Using Library of Antibody BindersBiocytogen, a Beijing-based biotechnology company listed on the Shanghai and Hong Kong stock exchanges, announced a strategic collaboration with Seattle-based Moonlight Bio to develop cutting-edge cell therapies for difficult-to-treat cancers. Under the agreement, Biocytogen will provide its off-the-shelf fully human antibody library against therapeutic targets while Moonlight Bio will lead preclinical development of the cell therapies. This partnership demonstrates the versatility and broad applicability of Biocytogen's antibody discovery platforms beyond traditional drug modalities for developing transformative cancer treatments.BioSpaceBiocytogen Announces Strategic Collaboration with Moonlight Bio to Advance Cell Therapies Using Library of Antibody BindersBiocytogen Pharmaceuticals, a Beijing-based biotechnology company listed on the SSE and HKEX, announced a strategic collaboration with Seattle-based Moonlight Bio, Inc. to develop cutting-edge cell therapies for difficult-to-treat cancers. Under the agreement, Biocytogen will provide its off-the-shelf fully human antibody library against therapeutic targets while Moonlight Bio will lead preclinical development of the resulting cell therapies. The partnership combines Biocytogen's antibody discovery platforms with Moonlight Bio's cell therapy technologies to address solid tumor limitations.GlobeNewswireU.S. CAR T-Cell Therapies Market Grows at 30.4% CAGR, Soars USD 42.61 Billion by 2035The U.S. CAR T-cell therapies market is projected to grow from USD 3.43 billion in 2026 to USD 42.61 billion by 2035, representing a compound annual growth rate of 30.4%, driven by rising cancer incidence, robust R&D investments, and increasing FDA approvals for novel therapies. Key recent developments include Wa'ed Ventures leading a $10 million Pre-Series A investment in Kure Cells for faster CAR-T manufacturing platforms, Kincell Bio partnering with Moonlight Bio to advance T-cell therapy programs, and Citius Oncology securing distribution agreements with McKesson for its FDA-approved LYMPHIR therapy. The market faces challenges including high manufacturing costs, limited certified treatment centers, and restrictive reimbursement policies, particularly for Medicaid programs.Pharmaceutical TechnologyLeveragen and Moonlight Bio unite for T cell therapy developmentLeveragen and Moonlight Bio have announced a strategic partnership to develop T-cell therapies for challenging cancers, specifically targeting solid tumours. Under the agreement, Leveragen will utilize its Singularity Sapiens Mouse platform for antibody discovery while Moonlight Bio manages the preclinical development of the therapies. The collaboration aims to combine advanced cell engineering with optimized antibody generation to improve therapeutic efficacy.